EGFR and non-small cell lung carcinoma: Due to the vast enthusiasm associated with breakthroughs provided by immunotherapy in NSCLC patients, the anti-PD-1/PD-L1 antibodies have also been tested in patients carrying activating EGFR mutations who progressed after EGFR TKIs, but the benefit of nivolumab nor pembrolizumab could not be demonstrated [101,102].